Q linea AB Asset Resilience Ratio
Q linea AB asset resilience ratio. Q linea AB (QLINEA) has an Asset Resilience Ratio of 69.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See QLINEA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Q linea AB (2017–2025)
Asset resilience ratio of Q linea AB from 2017 to 2025. This chart shows how Q linea AB's Asset Resilience Ratio has changed over time. Read debt load of Q linea AB for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Q linea AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Q linea AB balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr258.11 Million | 69.82% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr258.11 Million | 69.82% |
Asset Resilience Insights
- Very High Liquidity: Q linea AB maintains exceptional liquid asset reserves at 69.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Q linea AB Industry Peers by Asset Resilience Ratio
Compare Q linea AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Q linea AB Asset Resilience Ratio by Year (2017–2025)
Q linea AB asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Q linea AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 69.82% | Skr258.11 Million ≈ $27.78 Million |
Skr369.67 Million ≈ $39.78 Million |
+52.48pp |
| 2024-12-31 | 17.34% | Skr25.66 Million ≈ $2.76 Million |
Skr147.99 Million ≈ $15.93 Million |
-17.98pp |
| 2023-12-31 | 35.33% | Skr81.95 Million ≈ $8.82 Million |
Skr231.98 Million ≈ $24.96 Million |
+0.08pp |
| 2022-12-31 | 35.24% | Skr73.09 Million ≈ $7.87 Million |
Skr207.39 Million ≈ $22.32 Million |
-0.34pp |
| 2021-12-31 | 35.58% | Skr166.03 Million ≈ $17.87 Million |
Skr466.63 Million ≈ $50.22 Million |
-38.86pp |
| 2020-12-31 | 74.45% | Skr306.89 Million ≈ $33.03 Million |
Skr412.23 Million ≈ $44.36 Million |
+19.30pp |
| 2019-12-31 | 55.15% | Skr206.48 Million ≈ $22.22 Million |
Skr374.41 Million ≈ $40.29 Million |
-38.43pp |
| 2018-12-31 | 93.58% | Skr504.44 Million ≈ $54.29 Million |
Skr539.07 Million ≈ $58.01 Million |
+57.77pp |
| 2017-12-31 | 35.81% | Skr6.59 Million ≈ $708.97K |
Skr18.40 Million ≈ $1.98 Million |
-- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more